Merck & Co.
AWARDS
NEWS
As fireworks illuminate the night skies across the United States this weekend in celebration of Independence Day, BioSpace takes a look at some of the highlights of the pharma industry from the first half of 2019 and earlier that provides millions of patients with the independence of health.
The month of July is a slow one for the U.S. Food and Drug Administration (FDA), at least in terms of scheduled approval dates. Here’s a look at the three PDUFA dates the agency has on its calendar for the month.
Merck anticipates Keytruda’s approved indications to more than double over the next five years and anticipates its oncology pipeline winning more than 50 approvals over the same time period.
While Merck’s Keytruda has racked up nearly 20 approvals from the U.S. Food and Drug Administration, there is some investor concern that the company is too dependent on the product for its future.
The lawsuit was joined by Merck, Eli Lilly and Amgen. The companies claim the Department of Health and Human Services does not have the legal authority to force the companies to comply with the new rule.
June is turning out to be a busy month for approvals for the U.S. Food and Drug Administration. The agency has a slate of PDUFA dates this week, including two for Merck alone. Here’s a look.
JOBS
IN THE PRESS